HLA Class II Antibodies Recruit G-CSF Activated Neutrophils for Treatment of B Cell Malignancies

References

• Davis T.A., Maloney D.G., Liles T.M., Czerwinski D.B., Levy R. Long-term remissions in patients treated with anti-idiotype monoclonal antibodies for Non-Hodgkin's lymphoma. Proc. of ASCO. 1996; 15: 67, (Abstract)
   Google Scholar
• McLaughlin P., Grillo-Lopez A.J., Czuezman M., Link B.K., Levy R., Dillman R.O., Ho A., Bennett J.M., Heyman M.R., Schilder R.J., Cabanillas F., Rogers J., Dallaire B.K. Preliminary report on 3 phase III pivotal trial of the anti-CD20 antibody IDEC-C2B8 in patients with relapsed low-grade or follicular lymphoma. Proc. of ASCO 1996; 15: 417, (Abstract)
   Google Scholar
• Riethmüller G., Holz E., Schlimock G., Schmiegel W., Raab R., Höffken K., Gruber R., Pichlmair H., Hirche H.B., Pichlmayr R. Monoclonal antihody (MAB) adjuvant therapy of Dukes C colorectal carcinoma: 7 year update of a prospective randomized trial. Proc. of ASCO. 1996; 15: 444, (Abstract)
   Google Scholar
• Grossbard M.L., Press O.W., Appelbaum F.K., Bernstein I.D., Nadler L.M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863–78
   PubMed Web of Science ®Google Scholar
• Dillman R.O. Antibodies as cytotoxic therapy. J. Clin. Oncol. 1994; 12: 1497–515
   PubMed Web of Science ®Google Scholar
• Kaminski M.S., Kitamura K., Maloney D.G., Campbell M.J., Levy R. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J. Immunol. 1986; 136: 1123–30
   PubMed Web of Science ®Google Scholar
• Van de Winkel J. G. J., Capel P. J. A. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 1993; 14: 215–21
   PubMedGoogle Scholar
• Junghans R.P., Anderson C.L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. USA 1996; 93: 5512–6
   PubMed Web of Science ®Google Scholar
• Guyre P.M., Graziano R.F., Vance B.A., Morganelli P.M., Fanger M.W. Monoclonal antibodies that bind to distinct epitopes on FcγR1 are able to trigger receptor function. J. Immunol. 1989; 143: 1650–5
   PubMed Web of Science ®Google Scholar
• Fanger M.W., Morganelli P. M. B., Guyre P.M. Bispecific antibodies. Crit. Rev., Immunol. 1992; 12: 101–24
   PubMed Web of Science ®Google Scholar
• Deo Y.M., Graziano R.F., Repp R., Van de Winkel J. G. J. Clinical significance of IgG receptors and FcγR-directed immunotherapies. Immunol. today 1996, (in press)
   Google Scholar
• Elsässer D., Valerius T., Repp R., Weiner G.J., Deo Y., Kalden J.R., Van de Winkel J. G. J., Stevenson G.T., Glennie M.J., Gramatzki M. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with G-CSF. Blood 1996; 87: 3803–12
   PubMed Web of Science ®Google Scholar
• Lichtenstein A. Granulocytes as possible effectors of tumor immunity. Human Cancer Immunology I, H.F. Oettgen. W.B. Saunders, Philadelphia, London, Toronto 1990; 731–746
   Google Scholar
• Pericle F., Kirken R.A., Epling-Burnette P.K., Blanchard D.K., Djeu J.Y. Direct killing of interleukin-2-transfected turnor cells by human neutrophils. Int. J. Cancer 1996; 66: 367–13
   PubMed Web of Science ®Google Scholar
• Ely P., Wallace P.K., Givan A.L., Graziano R.F., Guyre P.M., Fanger M.W. Bispecific-armed, interferon gamma-primed macrophage mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood 1996; 87: 3813–21
   PubMed Web of Science ®Google Scholar
• Barker E., Reisfeld R.A. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res. 1993; 53: 362–7
   PubMed Web of Science ®Google Scholar
• Brittenden J., Heys S.D., Ross J., Eremin O. Natural killer cells and cancer. Cancer 1996; 77: 1226–43
   PubMed Web of Science ®Google Scholar
• Guyre P.M., Morganelli P.M., Miller R. Recombinant immune interferon increases immunoglobulin Fc receptors on cultured human mononuclear phagocytes. J. Clin. Invest. 1983; 72: 393–7
   PubMed Web of Science ®Google Scholar
• Van de Winkel J. G. J., Boonen G. J.J. C., Janssen P. L. W., Vlug A., Hogg N.B., Tax W. J. M. Activity of two types of Fc Receptors, FcγRI and FcγRII, in human monocyte cytotoxicity to sensitized erythrocytes. Scand. 1. Immunol. 1989; 29: 23–31
   PubMed Web of Science ®Google Scholar
• Repp R., Valerius T., Sendler A., Gramatzki M., Iro H., Kalden J.R., Platzer E. Neutrophils express the high affinity receptor for IgG (Fc-gamma RI; CD64) after in vivo application of rhG-CSF. Blood 1991; 78: 885–9
   PubMed Web of Science ®Google Scholar
• Valerius T., Repp R., de Wit T. P. M., Berthold S., Platzer E., Kalden J.R., Grainatzki M., Van de Winkel J. G. J. Involvement of the high affinity receptor for IgG (FcγR1; CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood 1993; 82: 931–9
   PubMed Web of Science ®Google Scholar
• Stockmeyer B., Valerius T., Kepp K., Heijnen I. A. F. M., Deo Y., Kalden J.R., Gramatzki M.B., Van de Winkel J. C. J. Preclinical studies with FcγR bispecific antibodies and G-CSF primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. 1996, (submitted)
   Google Scholar
• Lieschke G.J., Burgess A.W. Drug therapy: granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating lactor (1+11). N. Engl. J. Med 1992; 327: 28 and 99
   Google Scholar
• Matsumoto Y., Saiki I., Murata J., Okuyaina H., Tamura M., Azuma I. Recombinant human granulocyte colony-stimulating factor inhibits the metastasis of hematogenous and non-hematogenous tumors in mice. Int. J. Cancer. 1991; 49: 444–9
   PubMed Web of Science ®Google Scholar
• Cavallo F., Giovarelli M., Gulino A., Vacca A., Stoppacciaro A., Modesti A., Forni G. Role of neutrophils and CD4+ T lymphocytes in the primary and secondary memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J. Immunol. 1992; 149: 3627–35
   PubMed Web of Science ®Google Scholar
• Colombo M.P., Ferrari G., Stoppacciaro A., Parenza M., Rodolfo M., Mavilio F., Parmiani G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med 1991; 173: 889–97
   PubMed Web of Science ®Google Scholar
• Stoppacciaro A., Melani C., Parenza M., Mastracchio A., Bassi C., Baroni C., Parmiani G., Colombo M.P. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte—T cell cooperation and T cell-produced interferon γ. J. Exp. Med. 1993; 178: 151–61
   PubMed Web of Science ®Google Scholar
• Schmidt K.C., Rasmussen J.W., Wedehye I.M., Frederiksen P.B., Pedersen N.T. Accumulation of Indium-111-labeled granulocytes in malignant tumors. J. Nucl Med. 1988; 29: 479–84
   PubMed Web of Science ®Google Scholar
• Weber J.S., Spears L., Deo Y., Link J.L. Phase I study of a HER-2/neu bispecific antibody with G-CSF in patients with metastatic breast cancer. Proc. of ASCO 1996; 15: 354, (Abstract)
   Google Scholar
• Valerius T., Repp R., Wieland G., Deo Y., Van de Winkel J. G. J., Kalden J.R., Lang N., Gramatzki M. Bispecific antibody MDX210 (FcγRI HER-2/neu) in combination with G-CSF: results of a phase I trial in patients with metastatic breast cancer. Proc. of ASCO 1996; 15: 108, (Abstract)
   Google Scholar
• Dearman R.J., Stevenson F.K., Wrightham M., Hamblin T.J., Glennie M.J., Stevenson G.T. Lymphokine-activated killer cells from normal and lymphoma subjects are cytotoxic for cells coated with antibody derivatives displaying human Fcγ. Blood 1988; 72: 1985–91
   PubMed Web of Science ®Google Scholar
• Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323–7
   PubMed Web of Science ®Google Scholar
• Mourad W., Geha R.S., Chatila T. Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule I -dependent cell adhesion. J. Exp. Med. 1990; 172: 1513–6
   PubMed Web of Science ®Google Scholar
• Gosselin E.J., Wardwell K., Rigby W. F. C., Guyre P.M. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor. IFN-γ, and IL-3. J. Immunol. 1993; 151: 1482–90
   PubMed Web of Science ®Google Scholar
• Waldor M.K., Shiram S., McDevitt H.O., Steinman L. In vivo therapy with monoclonal anti-I-A antihody suppresses immunc responaes to acetylcholine receptor. Proc. Natl. Acad. Sci. USA 1983; 80: 2713
   PubMed Web of Science ®Google Scholar
• Shiram S., Steinman L. Anti-I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to Ir genes. J. Exp Med. 1983; 158: 1362
   PubMed Web of Science ®Google Scholar
• Kruisbeek A.M., Titus J.A., Stephany D.A., Gause B.L., Longo D.L. In vivo treatment with monoclonal anti-I-A antibodies: disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-A and I-E antigens. J. Immunol. 1985; 134: 3605–14
   PubMed Web of Science ®Google Scholar
• Perry I.L., Greene M.I. Conversion of immunity to suppression by in vivo administration of I-A-subregion-specific antibodies. J. Exp. Med. 1982; 156: 480–91
   PubMed Web of Science ®Google Scholar
• Kruisbeek A.M., Bridges S., Carmen J., Longo D.L., Mond J.J. In vivo treatment of neonatal mice with anti-I-A antibodies interferes with the development of the class I, class 11, and M1s-reactive proliferating T cell subset. J. Immunol. 1985; 134: 3597–604
   PubMed Web of Science ®Google Scholar
• Waldor M.K., Hardy R.R., Hayakawa K., Steinman I., Herzenberg L.A. Disappearance and reappearance of B cells aftcr in vivo treatment with monoclonal anti-I-A antibodies. Proc. Natl. Acad. Sci. USA 1984; 81: 2855–8
   PubMed Web of Science ®Google Scholar
• Marx J.L. Suppressing autoimmunity in mice. Science 1983; 221: 843–5
   PubMed Web of Science ®Google Scholar
• Bridges S.H., Kruisheek A.M., Longo D.L. Selective in vivo antitumor effects of monoclonal anti-I-A antibody on a B cell lymphoma. J. Immunol. 1987; 139: 4242–9
   PubMed Web of Science ®Google Scholar
• Epstein A.L., Marder R., Winer J.N., Stathopoulos E., Chen F.M., Parker J.W., Taylor C.R. Two new inonoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiag-nostic and immunotherapeutic potential. Cancer Res. 1987; 47: 830–40
   PubMed Web of Science ®Google Scholar
• Biddle W., Pancook J., Goldrosen M., Han T., Foon K.A., Vaickus L. Antibody-dependent, ccll mediated cytotoxicity by an anti-classII murine monoclonal antibody: effects of rccombinant interleukin 2 on human effector cell lysis of human B-cell tumors. Cancer Res. 1990; 50: 2991–6
   PubMed Web of Science ®Google Scholar
• Ottonello I., Moronc P., Dapino P., Dallegri F. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine-exposed inononuclear and neutrophilic polymor-phonuclear leukocytes. Blood 1996; 87: 5171–8
   PubMed Web of Science ®Google Scholar
• Ceinerlic D., Dadey B., Hen T., Vaickus I. Cytokine influence on killing of fresh chronic lymphocytic leukemia cells by human leukocytes. Blood 1991; 77: 2707–15
   PubMed Web of Science ®Google Scholar
• Gill I., Agah R., Hu E., Mazumder A. Synergistic effects of interleukin 2 and the monoclonal Lym-l against human Burkitt lymphoma cells in vitro and in vivo. Concer Res. 1989; 49: 5377–9
   PubMed Web of Science ®Google Scholar
• Hu E., Epstein A.L., Naeve G.S., Gill I., Martin S., Sherrod A., Nichols P., Chen D., Mazumder A., Levine A.M. A phase la clinical trial of Lym-l monoclonal antihody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 1989; 7: 155–66
   PubMed Web of Science ®Google Scholar
• DeNardo G.L., DeNardo S.J., Macey D.J., Shen S., Kroger L.A. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131-I-Lym-1 as a model. Cancer 1994; 73: 1038–48
   PubMed Web of Science ®Google Scholar
• Press O.W., Eary J.F., Badger C.C., Martin P.J., Appelhaum F.R., Nelp W.B., Levy R., Miller R., Fisher D., Matthews D., Bernstein I.D. Radiolabdeled antibody therapy of human B cell lymphomas. Immunobiology of Proteins and Poptides 1991; VI: 91–7
   Google Scholar
• Hu P., Glasky M.S., Yun A., Alauddin M.M., Hornick J.L., Khawali L.A., Epstein A.L. A human-mouse chimeric Lyin-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum. Antibod. Hyhridomas 1995; 6: 57–67
   PubMedGoogle Scholar
• Gingrich R.D., Dahle C.E., Hoskins K.F., Senneff M.J. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood 1990; 75: 2375–87
   PubMed Web of Science ®Google Scholar
• Fanger M.W., Shen L., Graziano R.F., Guyre P.M. Cytotoxicity mediated by human Fc receptors for IgG. Immunol. today 1989; 10: 92–9
   PubMedGoogle Scholar
• Weiner G.J., DeGast G.C. Bispecific inonoclonal antibody therapy of B-cell malignancy. Leukemia and Lymphoma 1995; 16: 199–207
   PubMed Web of Science ®Google Scholar
• Daeron M., Latour S., Malhec O., Espinosa E., Pina P., Pasmans S., Fridman W.H. The same Tyrosine-Based Inhibition Motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995; 3: 635–46
   PubMed Web of Science ®Google Scholar
• Holliger P., Prospero T., Winter G. “Diabodies”: small bivalent and bispecific antibody fragments. Proc. Natl. Acad Sci. USA 1993; 90: 6441–8
   Web of Science ®Google Scholar
• Hombach A., Jung W., Pohl C., Renner C., Sahin U., Schmits R., Wolf J., Kapp U., Diehl V., Pfreundschuh M. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int. J. Cancer 1993; 55: 830–6
   PubMed Web of Science ®Google Scholar
• Hartmann F., Renner C., Jung W., Deisting C., Juwanh M., Pfreundschuh M. Responses of refractory Hodgkin's disease to treatment with an anti-CD30/CD16 bispecific antibody: results of a phase I/II study. Proc. of ASCO 1996; 15: 444, (Abstract)
   Google Scholar
• Stevenson G.T., Glennie M.J., Kan K.S. Chemically engineered chimeric and multi-Fab antibodies. Protein Enineering of Antibody Molecules, M. Clark. Academic Titles, NottinghamUK 1993; 127
   Google Scholar